Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.53 USD | +2.48% | +4.51% | -50.61% |
Apr. 08 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
Apr. 02 | Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.61% | 704M | |
+0.67% | 42.4B | |
+46.96% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- IRON Stock
- News Disc Medicine, Inc.
- Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge